Evidence map›Paper›PMID 41914156›Full record

ArticleJournal of immunology research2026

A Bead-Based Screening Platform for Identifying Monoclonal Antibodies That Disrupt PD-1/PD-L1 Interactions.

Veridiane M Pscheidt, Rodrigo B Gassen, José E Sacconi Nunes, Deise do Nascimento de Freitas, Valdir Barth, Fernanda B Frozza, Milena D Santos, Claudia P Nunes, Cristina B C Bonorino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Veridiane M PscheidtImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0002-1486-4198
Rodrigo B GassenImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0003-0513-1555
José E Sacconi NunesImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0003-2177-0648
Deise do Nascimento de FreitasImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0001-6210-8285
Valdir BarthDepartment of Microbiology, University of São Paulo, São Paulo, São Paulo, Brazil, usp.br.ORCID https://orcid.org/0000-0002-7410-1598
Fernanda B FrozzaImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0001-9718-7243
Milena D SantosImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0009-0001-4261-7178
Claudia P NunesImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0009-0005-4503-8533
Cristina B C BonorinoImmunotherapy Laboratory, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ufcspa.edu.br.ORCID https://orcid.org/0000-0003-2755-3978

Funding

Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 22/2551-0000388-5Ministério da Saúde 25000.172780/2019-38
6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) targeting immune checkpoint pathways such as programmed cell death protein 1 (PD-1)/PD-L1 are central to modern immunotherapy, yet scalable methods to assess their functional blockade remain limited. We present a bead-based flow cytometry assay for quantifying the inhibition of PD-1/PD-L1 interaction by antibodies. Recombinant human PD-1 protein was conjugated to polystyrene beads, and its interaction with recombinant human PD-L1 protein labeled with a fluorochrome was measured. The inhibitory activity of an anti-PD-L1 mAb was quantified based on their ability to disrupt this interaction. The assay was validated for intra- and inter-assay precision, in addition, functionality was confirmed using a T cell coculture assay. The assay demonstrated dose-dependent inhibition by the αPD-L1 mAb, with a calculated mean IC

Indexed as

Antibodies, MonoclonalB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensCoculture TechniquesFlow CytometryHumansLectins, C-TypeProtein BindingT-LymphocytesAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteB7-H1 AntigenCD274 protein, humanCD69 AntigensImmune Checkpoint InhibitorsLectins, C-TypePDCD1 protein, humanProgrammed Cell Death 1 Receptorantibodiesflow cytometryimmune checkpoints inhibitorsimmunotherapyPD-L1

Identifiers

PMID41914156
PMCPMC13140367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.